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AbstrACt
Objective To identify differences in psychosocial, 
behavioural and clinical outcomes between patients with 
heart failure (HF) with and without stroke.
Design and participants A secondary analysis of 1023 
patients with heart failure enrolled in the Coordinating study 
evaluating Outcomes of Advising and Counselling in Heart 
failure.
setting Seventeen hospitals located across the Netherlands.
Outcomes measures Depressive symptoms (Centre for 
Epidemiological Studies Depression Scale), quality of life 
(Minnesota Living with Heart Failure Questionnaire, Ladder 
of Life Scale), self-care (European Heart Failure Self-Care 
Behaviour Scale), adherence to HF management (modified 
version of the Heart Failure Compliance Questionnaire) and 
readmission for HF, cardiovascular-cause and all-cause 
hospitalisations at 18 months, and all-cause mortality at 18 
months and 3 years.
results Compared with those without stroke, patients with 
HF with a stroke (10.3%; n=105) had twice the likelihood of 
severe depressive symptoms (OR 2.83, 95% CI 1.27 to 6.28, 
p=0.011; OR 2.24, 95% CI 1.03 to 4.88, p=0.043) at 12 and 
18 months, poorer disease-specific and generic quality of 
life (OR 2.80, 95% CI 1.61 to 4.84, p<0.001; OR 2.00, 95% CI 
1.09 to 3.50, p=0.019) at 12 months, poorer self-care (OR 
1.80, 95% CI 1.05 to 3.11, p=0.034; OR 2.87, 95% CI 1.61 to 
5.11, p<0.0011) and HF management adherence (OR 0.39, 
95% CI 0.18 to 0.81, p=0.012; OR 0.35, 95% CI 0.17 to 0.72, 
p=0.004) at 12 and 18 months, higher rates of hospitalisations 
and mortality at 18 months and higher all-cause mortality (HR 
1.43, 95% CI 1.07 to 1.91, p=0.016) at 3 years.
Conclusions Patients with HF and stroke have worse 
psychosocial, behavioural and clinical outcomes, notably 
from 12 months, than those without stroke. To ameliorate 
these poor outcomes long-term, integrated disease 
management pathways are warranted.
IntrODuCtIOn
Heart failure (HF) is an increasing pandemic 
characterised by high morbidity, mortality 
and poor quality of life.1 Stroke, the second 
leading global cause of death (11.8%) is a 
frequent comorbidity in patients with HF.2 
Stroke and HF commonly coexist because of 
shared vascular risk factors,3 4 and HF is associ-
ated with a twofold to threefold increased risk 
of ischaemic stroke5–8 and is an independent 
predictor of death and disability and hospital 
readmissions after stroke at 30 days.6 Around 
15% of patients with HF seen in HF clinics 
on a regular basis have a history of stroke.9 
Having both HF and stroke contributes to a 
worse prognosis.3 6 
Research has focused on the aetiology and 
pathophysiology of this comorbidity3 4 8 10 
rather than its psychosocial and behavioural 
characteristics. This is despite strong evidence 
linking factors such as depression and lack of 
social support to adverse outcomes in patients 
with stroke11 12 and HF,13 14 and attesting to 
the efficacy of psychosocial and behavioural 
interventions on outcomes such as psycholog-
ical adjustment, social support and lifestyle 
changes to reduce cardiovascular risk.15–17 
Attaining ideal cardiovascular health metrics 
strengths and limitations of this study
 ► A secondary analysis of data from one of the largest 
multicentre (n=17) randomised controlled trials of 
heart failure disease management.
 ► Comprehensive psychosocial, behavioural and clin-
ical outcome data.
 ► Absence of a measure of stroke severity may have 
impeded interpretation of clinical outcomes.
 ► Limited generalisability due to small proportion of 
patients with severe heart failure.
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such as quitting smoking and adopting a healthy diet can 
prevent up to 80% of cardiovascular disease,18 lower risk 
of total and cardiovascular disease mortality19 and lower 
rates of stroke, incident HF and lifetime risk of HF.20
Associations between lifestyle factors and HF and 
stroke, and their persistent poor prognosis, are well 
established, but evidence is deficient in psychosocial 
and behavioural comparisons of HF populations with 
and without stroke across the illness trajectory. Thus, we 
aimed to identify differences in psychosocial (depres-
sion, well-being, quality of life), behavioural (self-care, 
treatment adherence) and clinical (rehospitalisations, 
mortality) outcomes at baseline, 6, 12 and 18 months and 
mortality at 3 years between patients with HF with and 
without a history of stroke.
MethODs
study patients and trial procedures
Coordinating study evaluating Outcome of Advising and 
Counselling in Heart failure (COACH) was a multicentre 
(17 hospitals in the Netherlands), prospective randomised 
HF disease management trial designed to compare basic 
support and intensive support in patients with chronic 
HF using blinded end-point evaluation. Patients who 
were admitted for HF were enrolled in COACH before 
discharge, and randomised to care as usual or to one of 
two levels of care, basic or intensive, of nurse-led interven-
tion. Inclusion criteria were an admission for HF, evidence 
of a structural underlying heart disease and age ≥18 years. 
'History of stroke' was confirmed by medical records. 
Only those patients with complete data were included. 
The design and primary results of COACH have been 
described.21 22 All data collected were part of the orig-
inal COACH trial. The COACH trial was performed 
in accordance with principles outlined in the Declara-
tion of Helsinki and was approved by a central medical 
ethical committee, Medical Ethical Committee Gron-
ingen (MEtC) 2002/047, and also by the medical ethics 
committee in each participating centre. This secondary 
analysis of data was exempt from further ethics approval 
as no additional data was collected and no significant 
additional harm was posed to patients.
Patients were interviewed and medical records were 
examined to obtain relevant demographic, clinical, 
psychosocial and behavioural data at baseline (hospital 
discharge), 6, 12 and 18 months thereafter. Additionally, 
all-cause mortality data were collected at 3 years.
Data collection
Demographic and clinical data
Basic demographic (age, gender) and clinical data 
(comorbidities, cardiovascular risk factors, disease 
severity) were collected at baseline.
Psychosocial endpoints
Depressive symptoms were measured with the Centre for 
Epidemiological Studies Depression Scale (CES-D),23 a 
20-item clinically validated self-report questionnaire that 
assesses depressive symptoms in the general population 
and the medically ill. Scores range from 0 to 60; higher 
scores indicate more severe depressive symptoms. Cut-off 
scores of ≥16 indicating moderate depression and ≥24 for 
severe depression have been used extensively.24
Disease specific quality of life was measured with the 
Minnesota Living with Heart Failure Questionnaire 
(MLHFQ),25 a 21-item self-report questionnaire that 
assesses patients’ perceptions of the effects of their HF on 
quality of life. Degree of impairment on physical, social, 
psychological and socioeconomic domains is rated on 
a 6-point Likert scale from 0 (none) to 5 (very much); 
higher scores indicate poorer quality of life. A cut-off 
score of >45 indicates poor quality of life.26
Generic quality of life was measured with the Ladder 
of Life Scale (LLS),27 a 1-item measure of global well-
being. Individuals are asked to place themselves on an 
11-step ladder with ‘worst possible life’ representing the 
lowest rung (score=0) and ‘best possible life’ the top rung 
(score=10). The Ladder of Life has been used in various 
cardiovascular studies and is considered a valid measure 
of subjective well-being.28
Behavioural endpoints
Self-care was measured with the European Heart Failure 
Self-Care Behaviour Scale (EHFScBS-9),29 a 9-item self-re-
port questionnaire. The nine items are answered on a 
5-point Likert scale (1=completely agree; 5=completely 
disagree) and are converted to a standardised score 
ranging from 0 to 100 with a higher score indicating 
better self-care.30 Inadequate self-care behaviour has 
been identified as a standardised score below 70. A clini-
cally meaningful change is represented by a smallest real 
difference of 5.75 points in EHFScBS-9 scores.31 One 
internally consistent subscale can be identified in the 
EHFScBS, namely ‘consulting behaviours’. Consulting 
behaviours investigate how often people with HF call 
their doctor/nurse in case of shortness of breath, ankle 
swelling, weight gain and fatigue. The EHFScBS-9 has 
been implemented and validated across numerous coun-
tries world-wide.32
Adherence to HF management was measured with a 
modified version of the Heart Failure Compliance Ques-
tionnaire (HFCQ)33 that assesses adherence in: meeting 
appointments, taking medication, weighing, diet, fluid 
intake and exercise. Items were rated on a 5-point Likert 
scale (0=never, 1=seldom, 2=half of the time, 3=mostly, 
4=always). Content validity was established in a HF popu-
lation (Cronbach’s α=0.68).33Patients were classified as 
‘adherent’ if they selected ‘mostly’ or ‘always’ and were 
defined as ‘overall adherent’ if they adhered to at least 
four of the six behaviours.34
Clinical endpoints
Clinical endpoints comprised HF, cardiovascular and 
all-cause hospitalisations at 18 months, and all-cause 
mortality at 18 months and 3 years. An end-point 
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committee comprising two cardiologists and a geriatri-
cian adjudicated whether hospitalisations and death were 
related to HF, cardiovascular death or cardiovascular 
events. Data on all-cause mortality were collected from 
the hospital registry, general practitioner and/or munici-
pality at 3 years for each patient.
statistical analyses
A preliminary analysis using Χ2 statistic was conducted 
to identify differences in proportions of patients with HF 
with, and without, stroke across intervention and control 
groups (care as usual, basic support, intensive support 
groups). Descriptive values are presented as mean (±SD) 
for continuous variables or as percentages for categorical 
variables. Continuous variables were compared between 
patients with and without a history of stroke at baseline, 6, 
12 and 18 months using independent t-test, unequal vari-
ances t-test or Mann-Whitney U test where appropriate. A 
Bonferroni correction was applied to adjust for multiple 
comparisons across all baseline variables (p<0.002).
Variables with a p value less than 0.05 in the analysis 
comparing patients with HF with and without a history 
of stroke at baseline were consecutively subjected to a 
multivariate logistic regression model to assess the inde-
pendent impact of each risk factor on major or severe 
depressive status (CES-D ≥16 and CES-D ≥24). The vari-
ables age and gender were chosen a priori as covariates in 
each model. A variance inflation factor (VIF) was calcu-
lated to ensure that two or more explanatory variables 
included in a multiple logistic regression model were not 
highly correlated. If two patient characteristics showed 
high multicollinearity (VIF >3) the least significant vari-
able was excluded from the model. The model was esti-
mated using the stepwise backward method (Wald) with 
a p value of less than 0.05 to enter and a p value of 0.10 
to eliminate variables. This approach was repeated in 
order to identify significant predictors of: quality of life 
(MLHFQ25 and LLS),27 HF management adherence 
(HFCQ)33 and self-care behaviour (EHFScBS).29
Self-care subscale standardised scores of the EHFScBS 
were subjected to repeated measures analysis of covari-
ance, with scores at baseline, 12 and 18 months as the 
dependent variable, HF with a history of stroke as the 
between-subjects factor, and significantly different vari-
ables with a p-value less than 0.05 at baseline, with the 
addition of age and gender (chosen a priori) as covariates. 
Event rates for clinical endpoints for patients with HF 
with and without stroke were analysed for cardiovascular, 
HF and all-cause rehospitalisations at 18 months, and 
for all-cause mortality at 18 months and 3 years using 
Kaplan-Meier curves and compared with the log-rank 
test. HRs and 95% CI were calculated by means of the 
Cox proportional hazards regression model. The propor-
tional hazard assumption was tested based on Schoenfeld 
residuals. Variables showing a p value <0.1 derived from 
the univariate analysis, as well as sex and New York  Heart 
Association (NYHA) functional status, were included in 
multivariable Cox models. A more conservative p value 
was used to avoid overfitting the model. Data were anal-
ysed using SPSS V.22.
Patient and public involvement
This project involved secondary data analysis and thus did 
not involve patients. The study design and primary anal-
ysis are described elsewhere.21 22
results
Preliminary analyses
No differences in proportions of patients with HF with 
and without stroke across intervention and control groups 
were identified using Chi-square statistic.
Differences in hF patient characteristics with and without 
stroke
Of the 1023 patients enrolled in COACH, 105 (10.3%) 
had a documented history of stroke. Table 1 shows the 
baseline demographic and clinical characteristics. No 
significant differences were found for psychosocial or 
behavioural variables between patients with HF with and 
without stroke. Significant differences were found for the 
comorbidities type 2 diabetes, peripheral artery disease 
and transient ischaemic attack, with higher proportions 
among patients with HF with a history of stroke.
Differences in depressive symptoms
Table 2 shows the effect of the adjustment for multiple 
potential confounding variables on moderate and severe 
depression (CES-D). History of stroke was the only factor 
that remained in the model at both 12 and 18 months for 
risk of depression. This was most notable at 12 months 
with more than a twofold increased risk for both moderate 
(OR 2.29; 95% CI 1.22 to 4.29, p=0.010) and severe (OR 
2.83; 95% CI 1.27 to 6.28, p=0.011) depression. Type 2 
diabetes was found to have an independent association 
with moderate depression at 18 months (OR 1.63; 95% CI 
1.02 to 2.61, p=0.040).
Differences in quality of life
History of stroke was the only factor that remained in 
the model at 12 and 18 months. The 12 month point was 
found to have the highest increased risk for disease-spe-
cific (OR 2.80; 95% CI 1.61 to 4.84, p<0.001) and generic 
(OR 2.00, 95% CI 1.09 to 3.50, p=0.019) poor quality of 
life.
Differences in hF management adherence and hF self-care 
behaviour
History of stroke was the only factor to show an indepen-
dent association with inadequate HF management adher-
ence total scores at both 12 (OR 0.39, 95% CI 0.18 to 0.81, 
p=0.012) and 18 (OR 0.35, 95% CI 0.17 to 0.72, p=0.004) 
months (table 3). However, at 18 months comorbid tran-
sient ischaemic attack (OR 0.40, 95% CI 0.19 to 0.78) and 
history of atrial fibrillation (OR 1.79, 95% CI 1.04 to 3.07, 
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Table 3 shows the association between history of stroke 
and inadequate HF self-care at all time-points, with a 
1.8-fold risk at 12 months (OR 1.80, 95% CI 1.05 to 3.11, 
p=0.034) increasing to an almost threefold risk at 18 
months (OR 2.87, 95% CI 1.61 to 5.11, p<0.001). Other 
significant predictors of inadequate HF self-care were age 
at baseline and 12 months, 1.02-fold increased risk on 
both occasions, and comorbid peripheral arterial disease 
at 18 months, 1.65-fold increased risk.
Differences in clinical outcomes
Table 4 shows patients with HF with stroke fared worse 
across all rehospitalisations at 18 months compared with 
those without stroke; unadjusted HRs indicated greater 








  Age mdn (IQR) 73 (57–89) 75 (63–87) 0.069
  Male 569 (62%) 70 (67%) 1.23 (0.80 to 1.88) 0.348
  Married/living together 542 (60%) 63 (61%) 0.97 (0.64 to 1.46) 0.872
Comorbidities
  Type 1 diabetes mellitus 94 (10%) 14 (13%) 1.35 (0.74 to 2.46) 0.330
  Type 2 diabetes mellitus 153 (17%) 33 (31%) 2.29 (1.47 to 3.58) <0.001
  Transient ischaemic attack 59 (6%) 24 (23%) 4.31 (2.55 to 7.30) <0.001
  COPD 238 (26%) 30 (29%) 1.14 (0.73 to 1.79) 0.559
  History of atrial fibrillation 392 (43%) 59 (56%) 1.72 (1.15 to 2.59) 0.008
  Asthma 36 (4%) 5 (5%) 1.23 (0.47 to 3.19) 0.678
  Renal disease 68 (7%) 10 (10%) 1.32 (0.66 to 2.64) 0.440
  Liver disease 23 (3%) 3 (3%) 1.15 (0.34 to 3.88) 0.828
  Gastro-intestinal disease 105 (11%) 16 (15%) 1.39 (0.79 to 2.46) 0.255
  Hypertension 385 (42%) 54 (51%) 1.47 (0.98 to 2.20) 0.064
  Peripheral artery disease 139 (15%) 29 (28%) 2.14 (1.34 to 3.40) 0.001
Cardiovascular risk factors
  Body mass index 27.1±5 26.3±5 0.219
  Systolic blood pressure 118.2±21 119.3±19 0.623
  Diastolic blood pressure 68.5±12 67.5±11 0.448
Disease severity
  LVEF 33.7±14.3 33.9±15.1 0.930
NYHA classification 0.650
  II 465 (51%) 48 (47%)
  III 410 (45%) 51 (49%)
  IV 30 (3%) 4 (4%)
Previous HF admission 296 (32%) 38 (36%) 1.19 (0.78 to 1.82) 0.414
Medications
  ACE inhibitors  673 (73%) 71 (68%) 0.76 (0.49 to 1.17) 0.215
  Angiotensin blockers 110 (12%) 14 (13%) 1.13 (0.62 to 2.05) 0.688
  Beta-blockers 616 (67%) 61 (58%) 0.68 (0.45 to 1.03) 0.065
  Diuretics 878 (96%) 102 (97%) 1.55 (0.47 to 5.10) 0.468
  Coumarin 554 (60%) 71 (68%) 1.37 (0.89 to 2.11) 0.148
  Antidepressants 65 (7%) 6 (6%) 0.80 (0.34 to 1.88) 0.602
Bold p values represent significant alpha after Bonferroni correction (p<0.002).
ACE, angiotensin converting enzyme; COPD, chronic obstructive pulmonary disease; HF, heart failure; LVEF, left ventricular ejection; mdn, 
median; NYHA, New York Heart Association.
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odds of all rehospitalisations at 18 months, ranging from 
1.6 to 2.0. After adjusting for baseline age, sex, NYHA 
functional status and significant comorbidities patients 
with HF with stroke were up to 1.7 times more likely to 
be rehospitalised and 1.5 times more likely to experience 
all-cause mortality than patients with HF without stroke. 
The odds of all-cause mortality at 18 months and 3 years 
remained significantly higher in patients with HF with 
stroke compared with those without stroke (table 4). For 
example, at 3 years patients with HF with stroke had a 
43% greater likelihood of dying from all-cause mortality, 
compared with those without stroke.
Figure 1 shows significant differences between patients 
with HF with and without stroke for cardiovascular, HF and 
all-cause rehospitalisations up to 18 months and all-cause 
mortality up to 3 years. Kaplan-Meier survival curves 
show patients with HF with stroke fared worse than those 
without stroke across all clinical outcomes. Compared 
with those without stroke, rehospitalisations at 18 months 
for patients with stroke were on average 84 days earlier 
for cardiovascular rehospitalisations (mean 310 days, 
95% CI 265 to 355; mean 394 days, 95% CI 380 to 408, 
Log Rank 16.48 p<0.001), 61 days earlier for HF rehos-
pitalisations (mean 404 days, 95% CI 363 to 444; mean 
465 days, 95% CI 453 to 477, Log Rank 17.39 p<0.001) 
and 78 days earlier for all-cause rehospitalisations (mean 
261 days, 95% CI 218 to 304; mean 339 days, 95% CI 324 
to 354, Log Rank 13.31 p<0.001). In regard to all-cause 
mortality, over the 3 years patients with HF with stroke 
died 167 days earlier (mean 702 days, 95% CI 615 to 788) 
than patients with HF without stroke (mean 859 days, 
95% CI 833 to 884, Log Rank 15.78 p<0.001) and had a 
median survival time of 99 days less.
DIsCussIOn
This secondary analysis of COACH data showed an 
association between HF and stroke and psychosocial, 
behavioural and clinical outcomes. The patients with HF 
Table 2 Predictors of moderate and severe depression 
in final model of multivariable logistic regression over 18 
months
Predictors in final step of 




  Gender 1.60 (1.22 to 2.10) 0.001
  Age 0.99 (0.97 to 0.99) 0.037
  History of stroke 1.57 (1.03 to 2.41) 0.036
12 months
  History of stroke 2.29 (1.22 to 4.29) 0.010
18 months
  History of stroke 1.67 (0.92 to 3.04) 0.095




  Gender 1.68 (1.22 to 2.32) 0.002
  Age 0.98 (0.97 to 0.99) 0.010
12 months
  History of stroke 2.83 (1.27 to 6.28) 0.011
18 months
  Age 0.98 (0.96 to 1.00) 0.076
  History of stroke 2.24 (1.03 to 4.88) 0.043
Bold p values represent significant alpha, p<0.05. Covariates 
entered in each model: age at index hospitalisation; gender; 
comorbid transient ischaemic attack; comorbid peripheral arterial 
disease; comorbid type 2 diabetes mellitus; history of atrial 
fibrillation; and history of stroke.
CES-D, Center for Epidemiologic Studies Depression Scale.
Table 3 Predictors of inadequate heart failure management 
adherence and self-care behaviour in final model of logistic 
multivariable regression over 18 months
Predictors in final step of 
model OR (95% CI) P value
Inadequate HF 
management adherence 
(HFCQ;<3 of 6 behaviours32)
Baseline
  History of atrial fibrillation 1.30 (0.99 to 1.71) 0.060
12 months
  History of stroke 0.39 (0.18 to 0.81) 0.012
18 months
  History of stroke 0.35 (0.17 to 0.72) 0.004
  Comorbid TIA 0.40 (0.19 to 0.78) 0.008
  History of atrial fibrillation 1.79 (1.04 to 3.07) 0.035
Inadequate self-care behaviour (EHFScB-9;<7030)
Baseline
  Age 1.02 (1.01 to 1.03) 0.001
  History of stroke 1.49 (0.97 to 2.29) 0.069
12 months
  Age 1.02 (1.01 to 1.03) 0.009
  History of stroke 1.80 (1.05 to 3.11) 0.034
18 months
  History of stroke 2.87 (1.61 to 5.11) <0.001
  Comorbid peripheral 
arterial disease
1.65 (1.05 to 2.60) 0.030
Bold p values represent significant alpha, p<0.05. Covariates 
entered in each model: age at index hospitalisation; gender; 
comorbid transient ischaemic attack; comorbid peripheral arterial 
disease; comorbid type 2 diabetes mellitus; history of atrial 
fibrillation; and history of stroke.
EHFScB-9, European Heart Failure Self-care Behaviour scale; HF, 
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with a history of stroke had more comorbidities, poorer 
psychosocial and behavioural outcomes, earlier rehospi-
talisations and increased cardiovascular risk and mortality 
than patients with HF without stroke. Specifically, 
patients with HF with stroke had a twofold likelihood 
of being depressed, poorer HF management adherence 
and self-care and almost twice the likelihood of earlier 
rehospitalisations and all-cause mortality after adjusting 
for demographic variables and comorbidities. Differ-
ences between the two groups across outcomes tended 
to exacerbate over time, most notably from 12 months, 
indicating this as a critical point of patient decline that 
necessitates early intervention.
Comorbidities such as diabetes and peripheral artery 
disease greatly increase the physical and mental burden 
already imposed on patients with HF with and without 
stroke.17 Like other studies, we found a higher prevalence 
of type 2 diabetes, peripheral artery disease and transient 
ischaemic attack in patients with HF and stroke.35 Even so, 
it should be noted that in our population, patients were not 
severely impaired (NYHA functional status) with no differ-
ences between patients with HF with and without stroke. 
These findings are most likely the result of initial assessments 
for eligibility to participate in COACH.21 In light of moderate 
disease severity and poor psychosocial, behavioural and clin-
ical outcomes, the likelihood is that populations with more 
severe HF may experience even more severe outcomes.
Depression may occur in one in every three stroke 
patients.17 In HF populations this estimate is known to 
be far greater.14 Additionally, levels of depression are 
also known to increase alongside the number of comor-
bidities.11 17 In our study, there was almost a threefold 
likelihood of patients with HF with stroke having severe 
depressive symptoms at 12 months, which declined only 
to over a twofold likelihood at 18 months. With its asso-
ciated poor treatment adherence, lack of energy and 
motivation and social withdrawal,11–13 sustained levels of 
depressive symptoms among patients with HF with stroke 
draw attention to the vulnerability of this population 
and the need for screening, referral and engagement 
in management strategies. Our finding that comorbid 
type 2 diabetes was a stronger predictor of more severe 
depression than other factors (history of atrial fibrilla-
tion, hypertension and peripheral artery disease) among 
patients with HF with stroke compared with those without 
is intriguing and warrants further study, though an addi-
tional comorbidity such as diabetes is likely to increase 
the burden on patients and may exacerbate depression, 
which is known to be high in patients with diabetes 
alone.36
People with conditions such as HF and stroke are 
commonly found to report poor quality of life and well-
being.37 Together, HF and stroke would likely augment 
any such impact, as found in our study. Similar to our 
findings on depression, patients with HF and stroke 
fared worse across both measures of quality of life at 12 
and 18 months, a finding aligned with previous studies, 
indicating the degree of the decrement in quality of life 
is often proportional to the severity of depressive symp-
toms.37 The enduring continuation of increased rehospi-
talisations may explain poor physical quality of life at 18 
months for this patient population.6–9 In light of the poor 
prognosis of patients with HF and stroke, where symp-
toms can at best be controlled rather than cured, efforts 
to maintain and improve quality of life should be consid-
ered a primary goal in their disease management.
Achieving optimal self-care by patients with HF is widely 
regarded as essential goal of disease management.1 33 38 
However, HF self-care behaviour is complicated by factors 
such as ageing, comorbidities, cognitive impairment, 
frailty and limited social support.38 Our findings high-
light the difficulty of maintaining adequate HF self-care 
and management adherence. Together with stroke, a 
history of atrial fibrillation, comorbid transient ischaemic 
attack and peripheral artery disease contributed to defi-
ciencies in these aspects of care. This is likely due to the 




(unadjusted) P  value 
HR
(95% CI) adjusted: 








  CV rehospitalisation 373 (41%) 60 (57%) 1.74 (1.32 to 2.29) <0.001 1.45 (1.09 to 1.94) 0.012
  HF rehospitalisation 218 (24%) 42 (40%) 1.99 (1.43 to 2.78) <0.001 1.66 (1.17 to 2.36) 0.005
  All-cause rehospitalisation 495 (54%) 72 (69%) 1.57 (1.23 to 2.02) <0.001 1.31 (1.01 to 1.70) 0.044
  HF rehospitalisation/death 344 (38%) 67 (64%) 2.04 (1.57 to 2.66) <0.001 1.68 (1.27 to 2.22) <0.001
  All-cause mortality 230 (25%) 42 (40%) 1.78 (1.28 to 2.48) <0.001 1.46 (1.03 to 2.07) 0.033
3 years post-discharge
  All-cause mortality 354 (39%) 59 (56%) 1.75 (1.33 to 2.31) <0.001 1.43 (1.07 to 1.91) 0.016
*Other comorbidities; type 2 diabetes mellitus, transient ischemia attack, peripheral artery disease, history of atrial fibrillation.
CV, cardiovascular; HF, heart failure; NYHA, New York Heart Association.
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additive impact of major chronic disabling conditions 
contributing to a more burdensome and complex HF 
management and self-care regimen. This issue needs to 
be considered carefully when planning with patients and 
carers how best to optimise disease management strat-
egies. Patients with HF and stroke had poorer engage-
ment in HF self-care and management adherence from 
12 months, compared with those without stroke, with 
differences between the two groups in HF self-care 
being clinically significant according to interpretability 
of the EHFScBS-9.31 This may be explained by HF and 
stroke being established burdensome conditions,3 7 both 
requiring intensive and enduring support. Also, patients 
with HF and stroke, compared with those without stroke, 
had significantly more comorbidities, a known barrier 
to successful self-care.38 Thus, interventions which focus 
on prioritising specific aspects of self-care for HF and 
stroke independently may be more effective than general 
support for patients dealing with such burdensome and 
complex comorbidities.
In regard to clinical outcomes, our findings of approx-
imately twice the increased risk of hospitalisation and 
mortality in patients with HF with stroke concur with 
those of other studies,5–8 such as one showing patients 
with stroke after HF had a 2.3 times higher risk of dying 
than patients without stroke5 and another showing the 
odds of dying within 30 days and 1 year since stroke diag-
nosis, was close to two times greater for patients who had 
Figure 1 Kaplan-Meier event curves for patients with HF with (n=105) and without (n=918) stroke across (A) CV 
rehospitalisation by 18 months, (B) HF rehospitalisation by 18 months, (C) CV rehospitalisation or death by 18 months, and 
(D) all-cause mortality by 3 years as a function of HF and stroke comorbidity. Kaplan-Meier curves represent a comparison 
of patients with HF with (green) and without (blue) stroke, for days to rehospitalisation (A; B; C) or to death (D). Kaplan-Meier 
curves identified patients with HF with stroke as significantly (p<0.001) worse than patients with HF without stroke across 
all clinical outcomes. ‘Number at risk’ columns are in 200 day increments for rehospitalisation’s, and 400 day increments for 
mortality.  CV, cardiovascular; HF, heart failure.
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pre-existing HF.6 Additionally, in our study, comorbid HF 
and stroke was identified as a predictor of rehospitalisa-
tions at 18 months and all-cause mortality up to 3 years 
independent of age, gender, HF functional status and 
presence of other comorbidities such as peripheral artery 
disease, transient ischaemic attack and type 2 diabetes. 
Also, patients with HF and stroke were rehospitalised up 
to 84 days earlier and died an average of 5 months earlier 
compared with those without stroke.
Our findings highlight poor psychosocial, behavioural 
and clinical outcomes for patients with HF and stroke 
which, taken together, indicate a diminished likelihood 
of early and successful recovery. An assessment of the 
particular needs of this significant and growing patient 
group should inform the design of appropriately-tailored 
care management strategies, which can then be evaluated 
for effectiveness. Patient choice and preferences should 
be central to such efforts.
limitations
This was a secondary analysis of COACH data and there-
fore was constrained by the methods employed in the 
original study.21 22 Applicable to all observational trials, 
correlation does not prove causation. Although we found 
no statistically significant differences between propor-
tions of patients with HF with and without stroke across 
intervention and control groups, our study was limited 
by the lack of patients with severe HF, which may have 
caused a bias in terms of minimising the magnitude of 
the effects on outcome. Also, the absence of a measure 
of stroke severity, a known predictor of functional 
dependency,35 may have impeded our interpretation of 
clinical outcomes. Another limitation is the absence of 
recurrent stroke or mortality due to stroke as a clinical 
outcome measure. It would be valuable information to 
know if patients with HF and stroke were more likely to 
have recurrent stroke, as this could potentially influence 
depression, quality of life, adherence to HF care and clin-
ical outcomes. Using the medical record to determine 
the presence or absence of prior stroke does not capture 
severity and may be inaccurate due to poor history taking 
or documentation and this may have influenced the find-
ings. This is an important consideration when patients 
with ‘history of stroke’ in their medical record were more 
likely to have severe stroke. Lastly, although clinical inter-
view, the gold standard, was not used to diagnose depres-
sion, presence of depressive symptoms was assessed via 
the CES-D which has been well-validated, in both HF and 
stroke populations,24 to identify patients who are at high 
risk of developing a depressive disorder.
COnClusIOns
To our knowledge, this is the first study to examine psycho-
social, behavioural and clinical outcomes in patients with 
HF with stroke compared with those without stroke. 
These findings not only confirm the poor prognosis in 
patients with HF with stroke, but also that depression 
is more common, quality of life, HF self-care and HF 
management adherence are poorer and risk of rehos-
pitalisation and mortality are greater in these patients. 
Further, 12 months post-discharge was identified as a 
point of heightened vulnerability for those experiencing 
this comorbidity that may be ameliorated by strategies 
that address cardiovascular risk and psychosocial and 
behavioural factors. This study highlights the clinical rele-
vance of the complex interplay between HF and stroke 
that requires further investigation and warrants the need 
for long-term, integrated disease management pathways 
for patients with comorbid HF and stroke which span the 
hospital-home interface.
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